Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 7
2003 5
2004 9
2005 9
2006 7
2007 3
2008 5
2009 8
2010 3
2011 4
2012 11
2013 13
2014 8
2015 8
2016 10
2017 7
2018 11
2019 10
2020 12
2021 22
2022 22
2023 13
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.
de Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Wiendl H, Keller B, Roy S; MAGNIFY-MS Study Group. de Stefano N, et al. Among authors: achiron a. Neurol Neuroimmunol Neuroinflamm. 2022 Jun 14;9(4):e1187. doi: 10.1212/NXI.0000000000001187. Print 2022 Jul. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35701185 Free PMC article.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Cerebral Cavernous Malformations.
Ganmore I, Achiron A. Ganmore I, et al. Among authors: achiron a. N Engl J Med. 2017 Jul 6;377(1):71. doi: 10.1056/NEJMicm1613312. N Engl J Med. 2017. PMID: 28679101 Free article. No abstract available.
[Benign multiple sclerosis].
Winder G, Achiron A. Winder G, et al. Among authors: achiron a. Harefuah. 2011 May;150(5):463-5, 490, 489. Harefuah. 2011. PMID: 21678644 Review. Hebrew.
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, Gouider R, Hacohen Y, Hellwig K, Hemmer B, Kappos L, Ladeira F, Lebrun-Frénay C, Louapre C, Magyari M, Mehling M, Oreja-Guevara C, Pandit L, Papeix C, Piehl F, Portaccio E, Ruiz-Camps I, Selmaj K, Simpson-Yap S, Siva A, Sorensen PS, Sormani MP, Trojano M, Vaknin-Dembinsky A, Vukusic S, Weinshenker B, Wiendl H, Winkelmann A, Zuluaga Rodas MI, Tintoré M, Stankoff B. Tur C, et al. Among authors: achiron a. Mult Scler. 2022 Aug;28(9):1424-1456. doi: 10.1177/13524585211069068. Epub 2022 Feb 23. Mult Scler. 2022. PMID: 35196927 Review.
Polymerase-1 pathway activation in acute multiple sclerosis relapse.
Achiron A, Zilkha-Falb R, Feldman A, Bovim M, Rozen O, Sarova-Pinhas I, Magalashvili D, Dolev M, Menascu S, Gurevich M. Achiron A, et al. Autoimmun Rev. 2018 Dec;17(12):1235-1239. doi: 10.1016/j.autrev.2018.07.006. Epub 2018 Oct 11. Autoimmun Rev. 2018. PMID: 30316990 Review.
Safety of intravenous immunoglobulin (IVIG) therapy.
Katz U, Achiron A, Sherer Y, Shoenfeld Y. Katz U, et al. Among authors: achiron a. Autoimmun Rev. 2007 Mar;6(4):257-9. doi: 10.1016/j.autrev.2006.08.011. Epub 2006 Aug 28. Autoimmun Rev. 2007. PMID: 17317619 Review.
T-cell vaccination in multiple sclerosis.
Achiron A, Mandel M. Achiron A, et al. Autoimmun Rev. 2004 Jan;3(1):25-32. doi: 10.1016/S1568-9972(03)00060-0. Autoimmun Rev. 2004. PMID: 14871646 Review.
179 results